Incidence and Outcomes of Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Registry-based Descriptive Trial in Kobe City
- PMID: 37648538
- PMCID: PMC10725825
- DOI: 10.2176/jns-nmc.2023-0090
Incidence and Outcomes of Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Registry-based Descriptive Trial in Kobe City
Abstract
The current study aims to evaluate the incidence and results of aneurysmal subarachnoid hemorrhage (aSAH) throughout Kobe City. Based on a multicenter retrospective registry-based descriptive trial involving all 13 primary stroke centers in Kobe City, patients with aSAH treated between October 2017 and September 2019 were studied. A total of 334 patients were included, with an estimated age-adjusted incidence of 11.12 per 100,000 person-years. Curative treatment was given to 94% of patients, with endovascular treatment (51%) preferred over surgical treatment (43%). Of the patients, 12% were treated by shunt surgery for sequential hydrocephalus with a worse outcome at 30 days or discharge (14% vs. 46%, odds ratio (OR): 0.19, 95% confidence interval (CI): 0.088-0.39, p-value <0.001). As for vasospasm and delayed cerebral ischemia, most patients were given intravenous fasudil infusion (73%), with endovascular treatment for vasospasm in 24 cases (7.2%). The fasudil group had more good outcomes (42% vs. 30%, OR: 1.64, 95% CI: 0.95-2.87, p-value = 0.075) and significantly less death (3.3% vs. 35%, OR: 0.064, 95% CI: 0.024-0.15, p-value <0.001) at 30 days or discharge. Mortality rose from 12% at 30 days or discharge to 17% at 1 year, but neurological function distribution improved over time (modified Rankin Scale 0-2 was 39% at 30 days or discharge, 53% at 60 days, and 63% at 1 year). Our retrospective registered trial presented various statistics on aSAH, summarizing the current treatment status and prognosis.
Keywords: hydrocephalus; intracranial aneurysm; intracranial vasospasm; prognosis; subarachnoid hemorrhage.
Conflict of interest statement
Dr. Ohta has received lecturer's fees from Medtronic Japan, Daiichi Sankyo, Johnson & Johnson, Terumo, Stryker Japan, Tokai Medical, Otsuka, Takeda, Eisai, Kaneka, Bristol-Myers Squibb, AstraZeneca, Japan Lifeline, Kowa, Nipro, Century Medical, and Idorsia outside of the submitted work.
Dr. Imamura has received lecturer's fees from Medtronic Japan, Daiichi Sankyo, Johnson & Johnson, Terumo, Stryker Japan, and Asahi Intecc outside of the submitted work.
Dr. Sakai has received a research grant from Biomedical Solutions, Medtronic, Terumo, and TG Medical; lecturer's fees from Asahi-Intec, Biomedical Solutions, Kaneka, Medtronic, Idorsia, and Terumo; and membership on the advisory boards for Johnson & Johnson, Medtronic, and Terumo outside the submitted work.
The other authors do not declare any conflicts of interest.
All authors have registered online self-reported COI Disclosure Statement Forms through the website for JNS members.
Figures
Similar articles
-
Early permanent cerebrospinal fluid diversion in aneurysmal subarachnoid hemorrhage: does a lower rate of nosocomial meningitis outweigh the risk of delayed cerebral vasospasm related morbidity?Neurol Res. 2021 Jan;43(1):40-53. doi: 10.1080/01616412.2020.1819091. Epub 2020 Oct 26. Neurol Res. 2021. PMID: 33106124
-
Subarachnoid hemorrhage and the female sex: analysis of risk factors, aneurysm characteristics, and outcomes.J Neurosurg. 2014 Dec;121(6):1367-73. doi: 10.3171/2014.7.JNS132318. Epub 2014 Sep 12. J Neurosurg. 2014. PMID: 25216063
-
Association Between Neurological Outcomes Related to Aneurysmal Subarachnoid Hemorrhage and Onsite Access to Neurointerventional Radiology.World Neurosurg. 2018 May;113:e29-e37. doi: 10.1016/j.wneu.2018.01.121. Epub 2018 Feb 2. World Neurosurg. 2018. PMID: 29410100
-
Efficacy of Statins in Cerebral Vasospasm, Mortality, and Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.World Neurosurg. 2019 Nov;131:e65-e73. doi: 10.1016/j.wneu.2019.07.016. Epub 2019 Jul 8. World Neurosurg. 2019. PMID: 31295598
-
Simvastatin for the prevention of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a single-institution prospective cohort study.J Neurosurg. 2009 May;110(5):968-74. doi: 10.3171/2008.10.JNS08901. J Neurosurg. 2009. PMID: 19199459 Review.
Cited by
-
The Effectiveness and Safety of Tranexamic Acid in Treating Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.Healthcare (Basel). 2024 Dec 5;12(23):2452. doi: 10.3390/healthcare12232452. Healthcare (Basel). 2024. PMID: 39685074 Free PMC article. Review.
References
-
- Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. : Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43: 1711-1737, 2012 - PubMed
-
- Tenny S, Boktor SW: Incidence. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan. https://www.ncbi.nlm.nih.gov/books/NBK430746/ (Accessed Apr 14 2022) - PubMed